XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 5.20%82.67B | -4.83%19.54B | 0.16%20.77B | 13.15%20.73B | 13.87%21.63B | -12.56%78.59B | 0.15%20.53B | -9.59%20.74B | -29.39%18.32B | -7.30%19B |
Operating revenue | 4.85%81.29B | -5.38%19.16B | -0.45%20.36B | 13.02%20.4B | 13.83%21.36B | -12.94%77.53B | -0.24%20.25B | -9.99%20.45B | -29.82%18.05B | -7.56%18.77B |
Cost of revenue | 3.41%67.14B | -8.31%15.53B | -1.34%16.94B | 11.01%16.82B | 13.93%17.85B | -15.01%64.93B | -1.08%16.94B | -12.18%17.17B | -32.84%15.15B | -8.72%15.67B |
Gross profit | 13.70%15.53B | 11.57%4.01B | 7.36%3.84B | 23.37%3.91B | 13.59%3.78B | 1.34%13.66B | 6.39%3.59B | 5.31%3.57B | -6.41%3.17B | 0.03%3.33B |
Operating expense | 18.46%6.34B | 20.99%1.73B | 23.60%1.66B | 17.93%1.56B | 10.69%1.4B | -0.06%5.35B | -9.10%1.43B | 0.37%1.34B | 4.01%1.32B | 7.12%1.26B |
Selling and administrative expenses | 19.49%1.18B | 1.05%288M | 26.92%297M | 45.61%332M | 9.24%260M | -3.24%985M | 31.94%285M | -35.18%234M | 8.06%228M | 3.48%238M |
Other operating expenses | 18.22%5.16B | 25.96%1.44B | 22.90%1.36B | 12.16%1.23B | 11.02%1.14B | 0.69%4.37B | -15.63%1.14B | 13.57%1.11B | 3.21%1.09B | 8.01%1.03B |
Operating profit | 10.63%9.19B | 5.36%2.28B | -2.37%2.18B | 27.26%2.35B | 15.37%2.38B | 2.25%8.31B | 19.88%2.17B | 8.50%2.23B | -12.68%1.85B | -3.87%2.06B |
Net non-operating interest income expense | -21.22%-3.13B | -17.64%-807M | -31.01%-828M | -18.88%-762M | -17.61%-728M | -11.80%-2.58B | -15.88%-686M | -9.53%-632M | -10.90%-641M | -10.73%-619M |
Non-operating interest expense | 21.22%3.13B | 17.64%807M | 31.01%828M | 18.88%762M | 17.61%728M | 11.80%2.58B | 15.88%686M | 9.53%632M | 10.90%641M | 10.73%619M |
Other net income (expense) | 888.64%1.04B | -19.26%109M | 135.56%170M | 362.04%633M | 74.32%129M | -151.97%-132M | -49.63%135M | -512.82%-478M | -20.81%137M | 167.89%74M |
Gain on sale of security | -83.33%6M | --0 | -118.75%-6M | -91.43%3M | 145.00%9M | -87.71%36M | -10.00%-11M | -46.67%32M | -72.87%35M | -117.54%-20M |
Earnings from equity interest | -1.04%379M | -3.09%94M | -0.97%102M | -10.53%85M | 11.36%98M | 49.03%383M | 36.62%97M | 51.47%103M | 53.23%95M | 57.14%88M |
Special income (charges) | 181.95%522M | ---15M | --0 | 5,520.00%542M | -400.00%-5M | -65.03%-637M | --0 | -627.91%-626M | ---10M | 99.67%-1M |
-Less:Impairment of capital assets | 333.33%52M | ---- | ---- | 400.00%50M | ---- | -96.89%12M | ---- | ---- | --10M | ---- |
-Less:Other special charges | -98.08%12M | --1M | ---- | --6M | --5M | --625M | --0 | --625M | ---- | ---- |
-Write off | ---- | ---- | --0 | ---- | --0 | ---- | ---- | --1M | ---- | -99.67%1M |
-Gain on sale of property,plant,equipment | --586M | ---12M | --0 | --598M | ---- | --0 | --0 | --0 | --0 | ---- |
Other non- operating income (expenses) | 55.81%134M | -38.78%30M | 469.23%74M | -82.35%3M | 285.71%27M | -4.44%86M | -76.33%49M | 110.83%13M | 194.44%17M | -66.67%7M |
Income before tax | 26.96%7.11B | -1.92%1.58B | 35.50%1.52B | 65.47%2.22B | 17.33%1.78B | -7.82%5.6B | 8.91%1.61B | -19.94%1.12B | -21.49%1.34B | 2.71%1.52B |
Income tax | 78.55%541M | 189.36%136M | 15.58%89M | 110.19%227M | 25.35%89M | 48.53%303M | 4.44%47M | -6.10%77M | 25.58%108M | 888.89%71M |
Net income | 24.01%6.57B | -7.66%1.45B | 36.96%1.43B | 61.56%1.99B | 16.93%1.69B | -9.78%5.29B | 9.05%1.57B | -20.80%1.05B | -23.98%1.23B | -2.69%1.45B |
Net income continuous Operations | 24.01%6.57B | -7.66%1.45B | 36.96%1.43B | 61.56%1.99B | 16.93%1.69B | -9.78%5.29B | 9.05%1.57B | -20.80%1.05B | -23.98%1.23B | -2.69%1.45B |
Minority interest income | 28.84%1.75B | 54.17%370M | -45.79%251M | 110.56%678M | 35.33%452M | 22.21%1.36B | -14.89%240M | 46.52%463M | 8.78%322M | 53.21%334M |
Net income attributable to the parent company | 22.34%4.81B | -18.84%1.08B | 102.57%1.18B | 44.24%1.31B | 11.41%1.24B | -17.26%3.94B | 14.89%1.33B | -41.95%584M | -31.30%911M | -12.29%1.11B |
Preferred stock dividends | 33.33%4M | 0.00%1M | 1M | 0.00%1M | 0.00%1M | -25.00%3M | 0.00%1M | 0.00%1M | 0.00%1M | |
Other preferred stock dividends | -10.15%416M | -44.72%68M | -43.22%67M | 15.93%131M | 37.61%150M | 9.72%463M | 17.14%123M | 11.32%118M | 7.62%113M | 2.83%109M |
Net income attributable to common stockholders | 26.66%4.39B | -16.21%1.01B | 139.27%1.12B | 48.31%1.18B | 8.57%1.09B | -19.88%3.47B | 14.68%1.2B | -48.16%466M | -34.67%797M | -13.68%1B |
Basic earnings per share | 17.27%1.29 | -21.62%0.29 | 120.00%0.33 | 40.00%0.35 | 0.00%0.32 | -21.43%1.1 | 8.82%0.37 | -48.28%0.15 | -37.50%0.25 | -15.79%0.32 |
Diluted earnings per share | 17.43%1.28 | -21.62%0.29 | 113.33%0.32 | 40.00%0.35 | 0.00%0.32 | -22.14%1.09 | 8.82%0.37 | -48.28%0.15 | -35.90%0.25 | -13.51%0.32 |
Dividend per share | 3.24%1.275 | 3.20%0.3225 | 3.23%0.32 | 3.25%0.3175 | 3.28%0.315 | 41.95%1.235 | 17.92%0.3125 | 34.78%0.31 | 53.75%0.3075 | 74.29%0.305 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |